The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Roller https://sabrinakbcv771236.getblogs.net/72662026/elite-roller-pharma-the-hazardous-bet